-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Rubik's Cube Info
Author: Sunshine
On December 7, CDE's official website showed that Borui Medicine's BGC0228 clinical trial application was approved by the China Food and Drug Administration for the first time for the treatment of advanced malignant solid tumors
BGC0228 is a peptide coupling drug independently developed by Borui Medicine based on the targeted polymer coupling technology platform.
BGC0228 replaces the antibody with a polymer target head, and forms a new compound through peptide chain combined with traditional cytotoxic drugs, which achieves precise connection without falling off, and has a smaller molecular weight than ADC drugs, so that it can smoothly penetrate tumor cells and release drugs into tumor cell tissues.
Another class 1 new drug BGC0222 of Borui Biotechnology has entered the clinical stage.